Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Effcacy Evaluation of CO2 Removal in Combination With Continuous Veno-Venous Hemodialysis/Hemodiafiltration Therapy (A Clinical Study in Patients With Combined Renal Failure and Hypercapnia Due to Acute Lung Failure in COVID-19 and Other Forms of Respiratory Insufficiency)

NCT04871893 is registered in ClinicalTrials.gov with Fresenius Medical Care Deutschland GmbH as lead sponsor.

NCT NCT04871893
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04871893 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Effcacy Evaluation of CO2 Removal in Combination With Continuous Veno-Venous Hemodialysis/Hemodiafiltration Therapy (A Clinical Study in Patients With Combined Renal Failure and Hypercapnia Due to Acute Lung Failure in COVID-19 and Other Forms of Respiratory Insufficiency)
Lead sponsor
Fresenius Medical Care Deutschland GmbH
Phase
Not applicable
Overall status
Completed
Start date
March 25, 2022
Completion date
December 31, 2024
Enrollment
28 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

acute kidney injury, acute lung injury, covid19, hypercapnia